INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 245 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $714,169 | -21.3% | 22,586 | +1.5% | 0.01% | -14.3% |
| Q2 2023 | $907,355 | +18.6% | 22,250 | +8.4% | 0.01% | 0.0% |
| Q1 2023 | $764,743 | +13.6% | 20,519 | +6.3% | 0.01% | 0.0% |
| Q4 2022 | $673,482 | -35.1% | 19,303 | +4.0% | 0.01% | -36.4% |
| Q3 2022 | $1,038,000 | +10.5% | 18,552 | +2.2% | 0.01% | +22.2% |
| Q2 2022 | $939,000 | -28.6% | 18,151 | +0.3% | 0.01% | -18.2% |
| Q1 2022 | $1,316,000 | -37.5% | 18,105 | +1.7% | 0.01% | -31.2% |
| Q4 2021 | $2,105,000 | -6.1% | 17,801 | +6.5% | 0.02% | -11.1% |
| Q3 2021 | $2,241,000 | -16.5% | 16,708 | +0.8% | 0.02% | -18.2% |
| Q2 2021 | $2,683,000 | +143.0% | 16,569 | +20.4% | 0.02% | +120.0% |
| Q1 2021 | $1,104,000 | +49.0% | 13,759 | +1.0% | 0.01% | +42.9% |
| Q4 2020 | $741,000 | +171.4% | 13,628 | -0.7% | 0.01% | +133.3% |
| Q3 2020 | $273,000 | – | 13,724 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |